All In Biotech

Drug Trial Radar · NCT07871435

GI-102 (CD80-IgG4 Fc-IL2v3) in Combination With Pasritamig in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) (JET-201)

A Phase 1b/2, Open-label, Multi-center Study to Evaluate the Anti-cancer Activity, Safety and Tolerability of GI-102 (CD80-IgG4 Fc-IL2v3) in Combination With Pasritamig [T-CELL-Redirecting Agent Targeting Human Kallikrein 2 (KLK2)] in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Who Progressed on Previous Novel Hormonal Therapy (NHT) (JET-201)

Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

107

Planned (sponsor's estimate)

Start

Oct 12, 2026

Primary completion

Mar 31, 2029

Study completion Sep 30, 2029

Sponsor

Lead sponsor
GI Innovation, Inc.Industry
Sponsor type
Industry
Collaborators
Janssen Research & Development, LLC
First posted
Oct 13, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this clinical trial is to evaluate the safety, tolerability, and preliminary anti-cancer activity of GI-102 in combination with pasritamig in adult men with metastatic castration-resistant prostate cancer (mCRPC) whose cancer has progressed after previous treatment with a novel hormonal therapy (NHT).

Conditions

  • Metastatic Castration-resistant Prostate Cancer (mCRPC)

Interventions

  • GI-102Drug

    GI-102 will be administered in accordance with the procedures specified in the study protocol.

  • PasritamigDrug

    Pasritamig will be administered in accordance with the procedures specified in the study protocol.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and nature of DLTs (Safety run-in phase)Time frame: From Day -14 to Cycle 1 Day 22 (35 days)
  2. Incidence, nature, and severity of AEs graded according to CTCAE v6.0 (Safety run-in phase)Time frame: Up to 2 years
  3. PSA response rate (≥ 50% decline from baseline) per PCWG3 (Expansion phase)Time frame: Up to 2 years

Locations

6 sites in 2 countries. Site status is shown where the registry gives one.

  • Columbia University Medical Center

    New York, New York · Not yet recruiting

  • Yonsei University Health System, Severance Hospital

    Seoul, South Korea · Recruiting

  • Asan Medical Center

    Seoul, South Korea · Recruiting

  • The Catholic University of Korea Seoul ST.MARY'S Hospital

    Seoul, Banpo-daero, South Korea · Recruiting

  • Korea University Anam Hospital

    Seoul, Seongbuk-gu, South Korea · Recruiting

  • Ewha Womans University Mokdong Hospital

    Seoul, Yangcheon-gu, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.